High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.

Publication/Presentation Date

12-1-2019

Abstract

High-dose melphalan (MEL200) followed by autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces responses in MM resistant to other alkylators. Our prior Phase I trial adding bendamustine to MEL200 transplant conditioning resulted in no additional toxicity. We now report a single-arm, phase II study that evaluated the efficacy of bendamustine 225 mg/m

Volume

54

Issue

12

First Page

2027

Last Page

2038

ISSN

1476-5365

Disciplines

Medicine and Health Sciences

PubMedID

31190006

Department(s)

Department of Medicine, Lehigh Valley Topper Cancer Institute

Document Type

Article

Share

COinS